Bionet
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing… Read more
Market Cap & Net Worth: Bionet (1784)
Bionet (TWO:1784) has a market capitalization of $131.67 Million (NT$4.36 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17951 globally and #781 in its home market, demonstrating a -9.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bionet's stock price NT$86.60 by its total outstanding shares 50306000 (50.31 Million).
Bionet Market Cap History: 2015 to 2026
Bionet's market capitalization history from 2015 to 2026. Data shows growth from $54.00 Million to $131.67 Million (10.22% CAGR).
Bionet Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bionet's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Bionet's market cap is 0.10 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.44x
Bionet's market cap is 1.44 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $40.03 Million | $697.40 Million | -$6.27 Million | 0.06x | N/A |
| 2018 | $39.14 Million | $770.61 Million | $24.23 Million | 0.05x | 1.62x |
| 2019 | $60.52 Million | $775.56 Million | $6.80 Million | 0.08x | 8.90x |
| 2020 | $60.49 Million | $806.58 Million | $12.74 Million | 0.07x | 4.75x |
| 2021 | $59.53 Million | $921.42 Million | $26.62 Million | 0.06x | 2.24x |
| 2022 | $66.75 Million | $980.38 Million | $37.97 Million | 0.07x | 1.76x |
| 2023 | $88.34 Million | $1.13 Billion | $78.40 Million | 0.08x | 1.13x |
| 2024 | $120.88 Million | $1.22 Billion | $83.70 Million | 0.10x | 1.44x |
Competitor Companies of 1784 by Market Capitalization
Companies near Bionet in the global market cap rankings as of March 18, 2026.
Key companies related to Bionet by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Bionet Historical Marketcap From 2015 to 2026
Between 2015 and today, Bionet's market cap moved from $54.00 Million to $ 131.67 Million, with a yearly change of 10.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$131.67 Million | -16.33% |
| 2025 | NT$157.37 Million | +30.19% |
| 2024 | NT$120.88 Million | +36.83% |
| 2023 | NT$88.34 Million | +32.35% |
| 2022 | NT$66.75 Million | +12.12% |
| 2021 | NT$59.53 Million | -1.58% |
| 2020 | NT$60.49 Million | -0.06% |
| 2019 | NT$60.52 Million | +54.63% |
| 2018 | NT$39.14 Million | -2.22% |
| 2017 | NT$40.03 Million | -10.89% |
| 2016 | NT$44.92 Million | -16.81% |
| 2015 | NT$54.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bionet was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $131.67 Million USD |
| MoneyControl | $131.67 Million USD |
| MarketWatch | $131.67 Million USD |
| marketcap.company | $131.67 Million USD |
| Reuters | $131.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.